Dear Partners, Colleagues, and Friends,

As we come to the end of a very eventful year 2013, which marked DNDi’s 10th anniversary, I would like to begin by thanking all of you who contributed and participated in a series of meetings we held around the world in order to bring key actors together to reflect on the successes and challenges of the past decade, and on what the future directions should be for neglected disease R&D. Culminating with a conference organized in Nairobi with KEMRI in June and a conference organized in Paris with Institut Pasteur and MSF, in collaboration with PLOS, earlier this month, these meetings provided an excellent opportunity to take stock, measure progress, analyse roadblocks, and re-endorse the commitment of key actors worldwide to bringing the best science to the most neglected.

For DNDi, the year 2013 saw the inclusion of three treatments on the WHO Essential Medicines List (EML), notably ASMQ FDC for malaria, NECT for sleeping sickness, and the paediatric dosage form of benznidazole for Chagas disease; the distribution of ASAQ FDC for malaria reached distribution of over 250 million treatments since it was delivered six years ago; and two Phase II clinical trials on E1224 for Chagas disease and on a second combination for visceral leishmaniasis in Africa reached completion. DNDi’s pipeline this year contains 12 new chemical entities and nearly 30 projects covering six disease areas, thanks to the efforts of our team and all of the partners and donors who have contributed to a common vision of developing new treatments for neglected diseases.
 
Throughout the year, DNDi participated in international discussions on the future of R&D for neglected diseases, particularly at the WHO, through two policy articles. The first was a thorough analysis of the R&D pipeline for neglected diseases globally, ten years after an initial publication that coined the ‘Fatal Imbalance’. The second was a reflection on the DNDi model, based on the lessons learned after 10 years of experience in conducting R&D for neglected diseases through innovative approaches, and included the estimated costs of R&D of treatments delivered and in the pipeline.

As part of our 10-year anniversary activities, we called upon all of you to ‘connect to fight neglect’, and we are more grateful than ever to all of our generous donors, partners, colleagues, and friends for your commitment, energy, and talent that will continue to make the difference in bringing concrete solutions to neglected patients for the years to come.

I wish you all the best for 2014.

Bernard Pécoul
DNDi Executive Director